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Abstract
Background: A critical therapeutic challenge in epithelial ovarian carcinoma is the development of
chemoresistance among tumor cells following exposure to first line chemotherapeutics. The molecular and genetic
changes that drive the development of chemoresistance are unknown, and this lack of mechanistic insight is a
major obstacle in preventing and predicting the occurrence of refractory disease. We have recently shown that
Regulators of G-protein Signaling (RGS) proteins negatively regulate signaling by lysophosphatidic acid (LPA), a
growth factor elevated in malignant ascites fluid that triggers oncogenic growth and survival signaling in ovarian
cancer cells. The goal of this study was to determine the role of RGS protein expression in ovarian cancer
chemoresistance.
Results: In this study, we find that RGS2, RGS5, RGS10 and RGS17 transcripts are expressed at significantly lower
levels in cells resistant to chemotherapy compared with parental, chemo-sensitive cells in gene expression datasets
of multiple models of chemoresistance. Further, exposure of SKOV-3 cells to cytotoxic chemotherapy causes acute,
persistent downregulation of RGS10 and RGS17 transcript expression. Direct inhibition of RGS10 or RGS17
expression using siRNA knock-down significantly reduces chemotherapy-induced cell toxicity. The effects of
cisplatin, vincristine, and docetaxel are inhibited following RGS10 and RGS17 knock-down in cell viability assays and
phosphatidyl serine externalization assays in SKOV-3 cells and MDR-HeyA8 cells. We further show that AKT
activation is higher following RGS10 knock-down and RGS 10 and RGS17 overexpression blocked LPA mediated
activation of AKT, suggesting that RGS proteins may blunt AKT survival pathways.
Conclusions: Taken together, our data suggest that chemotherapy exposure triggers loss of RGS10 and RGS17
expression in ovarian cancer cells, and that loss of expression contributes to the development of chemoresistance,
possibly through amplification of endogenous AKT signals. Our results establish RGS10 and RGS17 as novel
regulators of cell survival and chemoresistance in ovarian cancer cells and suggest that their reduced expression
may be diagnostic of chemoresistance.
Background
Ovarian cancer is a solid malignancy often initially
responsive to cytotoxic chemotherapy, but the high 5-
year mortality rate (>55%) is a result in part of the
tumor cells’ ability to develop resistance to chemother-
apy. This “chemoresistance” is the specific acquired
resistance against the action of therapeutic agents (i.e.
cytotoxic chemotherapy) that makes further treatment
refractory. Its occurrence in patients with ovarian cancer
is unfortunately common because this disease has char-
acteristically dormant cells within the peritoneal cavity
that proliferate slowly, allowing for the development or
selection of resistance to aggressive treatment. Therefore
it is this pool of persistent, dormant, chemoresistant
cells that prevents the clinical and pharmacological abil-
ity to cure ovarian cancer [1]. The molecular and
genetic changes that drive the development of chemore-
sistance are unknown, and this lack of knowledge is a
major obstacle in preventing and predicting clinical
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Lysophosphatidic acid (LPA), an established mediator
of ovarian cancer cell growth and survival [2,3], is abun-
dantly present in the tumor microenvironment [4-7],
suggesting that amplification of autocrine or paracrine
LPA-mediated survival signaling could play a role in
chemoresistance. LPA functions by activating a family of
G-protein coupled receptors (GPCRs), which activate
heterotrimeric G-proteins to couple extracellular LPA to
activation of cellular signaling cascades such as MAP
kinase growth pathways and AKT survival pathways [8].
Like all GPCRs, LPA receptors trigger cellular responses
by stimulating the transition of G-proteins from their
inactive GDP-bound form to the active GTP-bound
form. Thus, G-proteins are the critical mediators of LPA
signaling cascades, and proteins that regulate G-protein
activity control the strength of LPA stimulated
responses in ovarian cancer cells.
A critical regulatory point in the G-protein activity
cycle is the deactivation of G-proteins by GTP hydroly-
sis, a step which is markedly enhanced in cells by
GTPase activating proteins (GAPs). Regulators of G-
protein Signaling (RGS) proteins are a highly diverse
family of proteins that function as GAPs to accelerate
the deactivation of heterotrimeric G-proteins, thus ter-
minating signaling initiated by GPCRs [9,10]. We have
recently shown that RGS proteins suppress LPA stimu-
lated growth signals in ovarian cancer cells [8,11], and
identified over a dozen RGS transcripts expressed in
ovarian cancer cells, many of which are differentially
expressed in normal ovarian cells versus ovarian cancer
cell lines [12]. Similarly, comparing RGS expression in
normal versus tumor tissue using existing databases
reveals significant changes in RGS expression during
ovarian cancer progression, suggesting RGS expression
levels are altered as ovarian epithelial cells undergo
oncogenic transformation [13].
Taken together, the ability of LPA to function as a
survival factor in ovarian cancer cells, the ability of RGS
proteins to suppress LPA stimulated G-protein activity,
and the differential expression of RGS proteins in ovar-
ian cancer cells suggest that changes in RGS expression
levels during ovarian cancer progression may regulate
the strength of LPA mediated survival signals and con-
tribute to chemoresistance. We hypothesized that if
expression of RGS proteins is decreased in ovarian can-
cer cells, this may amplify tonic constitutive LPA-
stimulated cell survival pathways, allowing cells to over-
come cytotoxicity. Indeed, we report here that gene
expression microarray analysis comparing chemother-
apy-sensitive and chemoresistant ovarian cancer cells
reveals downregulation of specific RGS transcripts dur-
ing acquired chemoresistance. We further demonstrate
that RGS10 and RGS17 expression regulates the cellular
toxicity of multiple cytotoxic chemotherapeutics, which
ultimately enhances the viability of these tumor cells in
the presence of chemotherapy. Finally, we observed that
RGS10 and RGS17 are able to suppress LPA-induced
activation of the survival factor AKT, suggesting a
mechanistic model for RGS10 and RGS17 control of
chemoresistance in ovarian cancer cells.
Methods
Cells and Reagents
We purchased SKOV-3 cells from American Type
Culture Collection (Manassas, VA). These cells were
maintained in McCoy’s 5A medium (Mediatech, Inc.,
Manassas, VA.) supplemented with 10% FBS (PAA
Laboratories, Inc., Etobicoke Ontario, Candada). Both
the parental and the MDR-HeyA8 cell line, a taxane-
resistant line generated by the long-term exposure to
paclitaxel, were kind gifts from Dr. Isaiah J. Fidler
(Department of Cancer Biology, University of Texas M.
D. Anderson Cancer Center, Houston, TX) and are pre-
sented elsewhere [14]. MDR-HeyA8 cells are maintained
in RPMI 1640 medium with 300 ng/mL paclitaxel with
15% FBS and HeyA8 cells are maintained in RPMI med-
ium with 15% FBS. Lysophosphatidic acid (18:1,
1-oleoyl-2-hydroxy-sn-glycero-3-phosphate) was pur-
chased from Avanti Polar Lipids, Inc. (Alabaster, AL)
and reconstituted in 0.1% fatty acid free BSA immedi-
ately prior to use. Cisplatin, docetaxel, paclitaxel and
vincristine were purchased from Sigma-Aldrich
(St. Louis, MO). siRNA was purchased from Ambion
(Austin, TX). RGS plasmids were purchased from the
UMR cDNA Resource Center (Rolla, MO).
Bioinformatics
Gene expression profiling data were acquired through
the NCBI Gene Expression Omnibus (GEO) DataSets.
The datasets GSE7556 [15], GSE15709 [16] and
GSE2058 (unpublished) were downloaded and mined
using Microsoft Excel prior to further analysis. Hier-
archical clustering analyses was performed using Cluster
developed by the Eisen lab [17] and the display of hier-
archical clustering graphs utilized TreeView [17] as pre-
viously described [18]. Visual representation of the data
into box plots was done with GraphPad Prism 5 (Graph-
Pad Software, Inc., La Jolla, CA).
RGS gene modulation
Transient transfections were performed using Fugene 6
transfection reagent (Roche Diagnostics, Basel Switzerland),
according to manufacturer’s instructions, at a ratio of 2
μL Fugene 6 reagent to 1 μg plasmid DNA. SKOV-3 cells
were plated in 24-well plates at 50,000 cells/well and
transfected with 500 ng HA-tagged RGS17 plasmid
DNA, 250 ng HA-tagged RGS10 plasmid DNA, or empty
vector. Assays were performed 48 hours after transient
Hooks et al. Molecular Cancer 2010, 9:289
http://www.molecular-cancer.com/content/9/1/289
Page 2 of 15
transfections, and total protein was isolated and pro-
cessed for immunoblotting to confirm expression with
HA epitope antibodies. For knock-down of RGS genes,
SKOV-3 cells were simultaneously plated and transfected
using siPORT NeoFX transfection reagent (Ambion,
Austin, TX) according to the manufacturer’s protocol for
reverse transfection. Cells were transfected in parallel
with RGS-targeted siRNA and negative control or
scrambled siRNAs for each experiment. A transfection
mix containing 10 nM siRNA and 2 μL siPORT NeoFX
reagent in OptiMem (Invitrogen) was added to each well
of a 24-well plate, followed by 30,000 cells in normal
growth medium. Cells and transfection mix were incu-
bated for 24 hours at 37°C at which point the media was
changed to fresh SKOV-3 growth medium and/or cells
were re-plated into either 96-well or 12-well plates.
Assays were performed and samples taken for transcript
expression analysis 72 h after transfection. Knock-down
experiments using siRNA in HeyA8 cells and in SKOV-3
AKT assays were performed using Dharmacon ON-TAR-
GETplus SMARTpools (Thermo Scientific, Lafayette,
CO) and transfected using Dharmafect reagent, accord-
ing to the manufacturer’s recommended protocols.
Cellular viability assays
Approximately 5,000 SKOV-3 cells were seeded in tripli-
cates in 96-well plates in 10% FBS DMEM and allowed
to attach for 24 hours prior to gene manipulation or
treatment with the indicated concentrations of cisplatin,
vincristine, paclitaxel or docetaxel for 48 hours. After 48
hours in the presence of chemotherapy, a cell viability
assay was conducted by removing all media from the
96-well plate and replacing it with serum free media
containing CellTiter-Blue® reagent (Promega Corpora-
tion, Madison, WI) as previously described [19] and
measured using SpectraMax M2 model microplate
reader (Molecular Devices, Sunnyvale, CA).
Quantitative real-time PCR
To determine the effect of acute cisplatin exposure on
SKOV-3 cells was determined, approximately 700,000
SKOV-3 cells were plated in 100 mm tissue culture
plates and allowed to attach over-night. The following
day, media was aspirated and replaced with 100 μM cis-
platin diluted in complete SKOV-3 media. After 24 or
48 hours of drug incubation, the media was aspirated
and 7 mL Trizol reagent (Invitrogen) was added. RNA
isolation was performed according to manufacturer’s
protocol. DNA was synthesized from 2 μg of total RNA
using the High Capacity Reverse Transcriptase cDNA
kit (Applied Biosystems) to amplify the mRNA. For
HeyA8 parental and multi-drug resistant cells, mRNA
was isolated using Trizol reagent (Invitrogen) and quan-
tified prior to cDNA synthesis. The cDNA was
synthesized using a Superscript II kit (Invitrogen) and a
Mastercycler Pro (Eppendorf AG, Hamburg, Germany).
Following cDNA synthesis, quantitative real-time poly-
merase chain reaction was performed using Superscript
III kit for RT-PCR (Invitrogen) and Master Mix contain-
ing Power SYBR Green reagent (Applied Biosystems,
Foster City, CA). Transcript expression was assessed
using a 7900HT Real-Time PCR System from Applied
Biosystems (now Life Technologies, Carlsbad, California).
Reactions were normalized using the housekeeping gene
GAPDH and calculations were performed according to
the ΔΔCT method. Primers used were based on algo-









Cells were plated and transfected with siRNA as
described above and then replated in 12-well plates for
~90% confluency. Cells were treated with various con-
centrations of cisplatin in complete media containing
10% serum for 48 hours. The medium was then
removed and cells were washed twice with PBS and
incubated in binding buffer (10 mM HEPES, 140 mM
NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, pH =
7.4) containing annexin V-FITC (25 μg/ml) and PI (25
μg/ml) for 10 min. Cells were washed three times in
binding buffer and released from the monolayers using
a rubber policeman. Cells were passed through a 35 μm
filter before being analyzed using a CyAN™ ADP Analy-
zer (Beckman Coulter, Brea, CA) to isolate and quantify
annexin-positive cells, and data were analyzed using
Flowjo Flow Cytometry Analysis software using estab-
lished methods [20]. For each data point 20,000 cells
were analyzed for SKOV-3 cells, and 50,000 cells were
analyzed per data point for HeyA8 cells.
AKT phosphorylation
SKOV-3 cells were plated in 24-well dishes at 75% con-
fluency and transfected with Fugene 6 expression plas-
mid complexes or plated in 96-well dishes and
transfected with siRNA complexes as described above.
Cells were serum starved overnight, and treated with
vehicle, 0.1 μMLPA or 1 μM LPA for five minutes at
37°C. Control wells were treated with LPA in the pre-
sence or absence of LY294002, an inhibitor of PI3
kinase. Media was then aspirated and cells were lysed in
SDS-PAGE sample buffer. The lysates were boiled for
five minutes and analyzed using SDS-PAGE and
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immunoblotting. Membranes were incubated with phos-
pho-AKT primary antibodies (Cell Signaling Technolo-
gies), and visualized using ECL reagents (Pierce).
Membranes were subsequently blotted with GAPDH
antibodies as a loading control.
Statistical analysis
Experimental data was analyzed for statistical differences
using an analysis of variance (ANOVA) followed by
Bonferroni’s Multiple Comparison test or Tukey’s test
between groups, where indicated. *p < 0.05 **p < 0.01
and ***p < 0.001 indicate the levels of significance.
Results
Analysis of RGS expression changes in ovarian cancer
models of chemoresistance
We have recently demonstrated that RGS proteins sig-
nificantly suppress LPA signaling in ovarian cancer cells
[8,11] and that LPA mediates AKT activation and survi-
val signals in cancer cells [8,21]. Given these connec-
tions, we explored possible roles for RGS proteins in
ovarian cancer chemoresistance. To determine whether
altered RGS expression correlates with acquired che-
moresistance, we assessed RGS expression in multiple
datasets downloaded from the NCBI Gene Expression
Omnibus DataSets that contain whole-genome expres-
sion data in cultured ovarian cancer cell lines before
and after acquired chemoresistance. Dataset GSE15709
describes changes in gene expression in parental chemo-
sensitive A2780 cells and A2780 cells resistance to cis-
platin using quintuplicate samples [16]. In the initial
study, Nephew and colleagues chronically treated drug-
sensitive cells with increasing concentrations of cisplatin.
Following multiple rounds of clonal selection of increas-
ingly resistant cells, they generated a multi-drug resistant
cell line. Analysis of changes in RGS gene expression
revealed that several RGS transcripts-RGS2, RGS3, RGS5,
RGS10, RGS12, RGS16, and RGS17-were decreased in
chemoresistant cells. These RGS transcripts were sufficient
to distinguish between parental and resistant cell lines in
hierarchical clustering analysis of expression data. To
select RGS probes distinguishing chemo-resistant from
parental cells, we first applied Welch’s t-test to all of the
probes contained within the array for RGS transcripts.
The result was then visualized with a heatmap after hier-
archical clustering (see Methods). This supervised
approach revealed a clear correlation between decreases in
selected RGS transcripts and the cisplatin-resistant pheno-
type (Figure 1A). We further compared the level of expres-
sion from individual RGS transcripts in parental A2780
and cisplatin-resistant cells using GSE15709 and determined
that RGS2, RGS5, RGS10, and RGS17 were significantly
lower in resistant cells than in parental cells (Figure 1A,
***p < 0.001, *p < 0.05). Multiple probes for RGS5 and
RGS10 were present on the array, distinguished in the figure
as RGS5 and RGS5’, and RGS10 and RGS10’.
To confirm these results, we assessed RGS expression
using an additional independent microarray gene
expression dataset. In GSE7556, transcript expression in
SKOV-3 cells with acquired chemoresistance to vincris-
tine was compared to parental vincristine-sensitive cells
[15]. Comparison of the changes among RGS transcripts
confirmed the reduction of RGS2, RGS5, RGS10 and
RGS17 in acquired chemoresistance, although the data
were determined in duplicate samples, limiting the sta-
tistical significance (Figure 1B).
To further confirm that expression of these RGS tran-
scripts is reduced in drug resistant cancer cells, we
directly measured expression of RGS transcripts in par-
ental Hey-A8 ovarian cancer cells and taxane-resistant
derivatives of this cell line (commonly referred to as
Multi-drug resistant or MDR-HeyA8 cells, although they
retain cisplatin sensitivity; see Additional file 1). RNA
was isolated from both cell lines, and transcript expres-
sion was quantified using real time RT-PCR as described
in Methods. We again found that RGS2, RGS10, and
RGS17 transcripts were significantly reduced in the
MDR-HeyA8 cell line; however, no change was observed
in RGS5 expression (Figure 1C). Taken together, these
data show that RGS2, RGS10, and RGS17 transcripts are
commonly downregulated in acquired chemoresistance
in three distinct ovarian cancer cell lines resistant to
three distinct chemotherapeutics, while RGS5 was
down-regulated in two of the models. This suggests that
these RGS proteins have a broad role in cell survival in
the presence of multiple chemotherapeutic agents.
Cisplatin treatment acutely lowers expression of RGS10
and RGS17 in ovarian cancer cells
The above analysis suggests a correlation between
acquired chemoresistance and decreased expression of
RGS2, RGS5, RGS10 and RGS17 transcripts. Lower
expression observed in chemoresistant cancer cells
could reflect acutely downregulated RGS transcripts or
selection for cells expressing reduced RGS transcripts.
To determine if exposure to chemotherapeutics acutely
causes inhibition of RGS transcripts, we treated SKOV-3
ovarian cancer cells with cisplatin for 24 and 48 hours,
isolated RNA, and quantified RGS transcript expression.
Cells were treated with 100 μM cisplatin, which repre-
sents approximately an IC80 dose, as determined by cell
viability dose response curves (see Additional file 2). As
shown in Figure 2, expression of RGS10 and RGS17 was
reduced following a 48 h exposure to cisplatin (*p <
0.05). Significant reductions in transcript levels were
also observed just 24 hours after cisplatin treatment
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Figure 1 RGS transcript expression is decreased in multiple models of ovarian cancer chemoresistance. (A) RGS expression is
decreased in cisplatin resistant A2780 cells. A hierarchical clustering heat map is shown depicting changes in RGS expression between
parental A2780 cells (n = 5) and chemoresistant (resistant) A2780 cells (n = 5). As indicated in the side bar, red coloring represents a high level
of comparative expression and green indicates a lower level (range 4.3 to -3.5). In the left panel, a box plot depicts the expression levels of
multiple RGS transcripts in parental and drug resistant A2780 cells exposed to long-term cisplatin. RGS2, 5, 10, and 17 were significantly down
regulated in repeated datasets and are presented here. Where multiple probes for the same gene were included on the microarray chip, these
are distinguished with (’). *p < 0.05, ***p < 0.001 between groups, parental vs. chemoresistant cells. (B) RGS expression is decreased in
vincristine-resistant SKOV-3 cells. A hierarchical clustering heat map is shown depicting changes in RGS expression between parental SKOV-3 cells
(n = 2) and chemoresistant SKOV-3 cells (n = 2). In the left panel, a box plot depicts the expression levels of multiple RGS transcripts in parental
(black bars) and vincristine resistant (open bars) SKOV-3 cells. (C) RGS expression is decreased in paclitaxel-resistant HeyA8 cells. RNA was isolated
from parental and MDR-HeyA8 cells as described, and the expression of RGS2, RGS5, RGS10 and RGS17 transcripts was normalized to b2-
microglobulin as an internal standard prior to the comparison between parental and multi-drug resistant HeyA8 cells. The fold change in
expression relative to vehicle controls was calculated by the 2-ΔΔCt method. *p < 0.05, normalized control vs. RGS groups.
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(data not shown). To assess whether the changes were
transient, we further determined the level of transcript
expression after treatment with 100 μM cisplatin for 48
hours as described above, followed by removal of the
drug and growth in fresh media for an additional 48
hours. Surprisingly, RGS10 and RGS17 transcript levels
remained significantly lower two days following removal
of the drug as compared to control cells, suggesting per-
sistent effects on RGS expression following cisplatin
exposure (Figure 2).
To determine the effects of more chronic exposure, we
also treated cells with IC30, IC50, and IC80 doses of cis-
platin for 72 and 96 hour incubations. Unfortunately,
exposure times greater than 48 hours using an IC80
dose led to significant cell death, and treatment of cells
with lower doses did not have a significant effect on
RGS10 and RGS17 transcript expression (data not
shown). No significant changes were observed in RGS2
or RGS5 expression following cisplatin exposure, and
changes in RGS10 and RGS17 were not consistently
observed following exposure to therapeutic doses of vin-
cristine or docetaxel (data not shown).
RGS10 and RGS17 expression levels regulate the
cytotoxicity of chemotherapeutics
We next determined if directly inhibiting RGS expression
could recapitulate the observed loss of chemosensitivity.
For the following experiments, we focused on RGS10 and
RGS17 because they were downregulated in three inde-
pendent models of chemoresistance, and, unlike RGS2,
they selectively deactivate Gi family G-proteins [22-24],
which are known to regulate survival pathways [8,25,26].
To determine if the loss of RGS10 and/or RGS17 expres-
sion could be directly linked to a change in sensitivity to
chemotherapeutics, we determined the effect of siRNA
mediated knock-down of RGS10 and/or RGS17 on cell
viability in the absence or presence of chemotherapeutics.
Transfection of siRNA duplexes targeted at RGS10 and
RGS17 resulted in 75-85% reduction of each respective
transcript whether transfected alone or in combination
(Figure 3A). We first assessed changes in cell viability
mediated by changes in RGS expression levels in the
absence of any chemotherapeutic drug. Reduced expres-
sion of either RGS10 or RGS17 resulted in significantly
higher cell viability 72 hours after siRNA transfection
(Figure 3B).
We further assessed the ability of RGS10 and RGS17
levels to affect cell death induced by three cytotoxic
chemotherapy agents: the platinum compound cisplatin,
the taxane compound docetaxel, and vincristine. Plati-
num and taxane compounds are used in first-line che-
motherapy regimens in ovarian cancer (paclitaxel usage
in ovarian cancer is an FDA-approved labeled indication
while docetaxel is off-label for this indication). Vincris-
tine is used for other tumor types (acute lymphoblastic
leukemia, Hodgkin’s lymphoma, multiple myeloma, etc.),
but was included in the analysis to determine how
broad the effects of RGS proteins were. SKOV-3 cells
display low sensitivity to cisplatin, requiring micromolar
doses for significant cell death. In contrast, these cells
are highly sensitive to vincristine and docetaxel (see
Additional file 2). Cell viability was determined follow-
ing 48 hour treatment with 100 μM cisplatin, 100 nM
vincristine, or 100 nM docetaxel in cells transfected
with either negative control siRNA, RGS10 siRNA,
RGS17 siRNA or both RGS siRNA constructs. The per-
cent cell viability (normalized to cell number in the
absence of drug, to account for the effect on overall cell
growth as shown above) was significantly higher in cells
with reduced RGS10 or RGS17 expression levels (Figure
3C). Dose response curves show that lowering either
RGS10 or RGS17 transcript levels resulted in a decrease
in the potency of cisplatin, vincristine, and docetaxel
(Figure 3D-F, Table 1). Simultaneous knock-down of
RGS10 and RGS17 did not markedly enhance the effect
Figure 2 Expression of RGS10 and RGS17 transcripts is acutely
and persistently downregulated in response to cisplatin
exposure. SKOV-3 cells were treated with vehicle or the IC80 dose
(100 μM) of cisplatin for 48 hours. RNA was isolated from the cells
either immediately (black bars), or after an additional subsequent 48
hour incubation in fresh media, in the absence of drug (striped
bars). The expression of RGS10 and RGS17 transcripts was
normalized to GAPDH internal standards. The fold change in
expression relative to vehicle controls was calculated by the 2-ΔΔCt
method. *p < 0.05, vehicle treated vs. cisplatin treated.
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Figure 3 SKOV-3 cell sensitivity to cytotoxic drugs is altered by modulating RGS10 and RGS17 expression levels. (A) Transcript levels of
RGS10 and RGS17 were determined using quantitative RT-PCR 72 hours after transient transfection with the indicated siRNA constructs. RGS
transcript levels were normalized to GAPDH transcripts and reported relative to negative control-siRNA treated cells. (B) Overall cell viability was
determined in SKOV-3 cells 48 hours following siRNA transfection in the absence of drug using CellTiter-Blue colorimetric cellular metabolism
assays. (C) Cytotoxic drugs were added to cells at the indicated doses 24 hours after siRNA transfection, and cell viability was determined 48
hours after addition of drug. Data are shown normalized to cell viability in the absence of drug (100%). *: p < 0.05, **: p < 0.01,***: p < 0.001.
(D-F) siRNA-mediated knock-down of RGS10 or RGS17 alone or in combination resulted in a right-shifted dose response curve of cisplatin (D),
vincristine (E), or docetaxel (F) toxicity in SKOV-3 cells.
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of individual knock-downs. These data suggest that
ovarian cancer cells may have survival signals which are
normally blunted by endogenous RGS10 and RGS17
expression. Notably, the fold decrease in RGS10 and
RGS17 transcript expression achieved following siRNA
treatment that led to this increase in cell survival is
comparable to that observed following cisplatin expo-
sure, indicating that cisplatin exposure itself may reduce
the sensitivity of SKOV-3 cells to cisplatin by inhibiting
RGS10 and RGS17 expression.
We next performed the reciprocal experiment by
overexpressing either RGS10 or RGS17 in SKOV-3 cells,
with the expectation that this may increase the potency
of cisplatin-induced cell death. Indeed, in some experi-
ments RGS10 and RGS17 overexpression did enhance
chemotherapeutic potency, but the effect was not con-
sistent, varying with transfection efficiency (data not
shown). It is possible that the endogenous levels of
RGS10 and RGS17 are sufficiently high to provide near-
maximal GAP activity, such that only extremely high
levels of transient transfection produce a significant
change in activity levels. Nonetheless, the decrease in
cytotoxicity of chemotherapeutics following RGS10 or
RGS17 knock-down clearly indicate that the suppression
of these proteins promotes cell survival and suggest a
decrease in the expression levels of RGS10 or RGS17
are sufficient to lower ovarian cancer cell sensitivity to
chemotherapeutic cytotoxicity.
RGS10 and RGS17 regulate chemotherapeutic-induced
cell death
The data above demonstrate that RGS10 and RGS17
expression alters sensitivity to chemotherapeutic-
induced cytotoxicity when assessed by viability assays,
which suggests a decrease in cell death. To more specifi-
cally evaluate the role of RGS proteins in regulating cell
death stimulated by chemotherapeutics, we assessed
chemotherapeutic induced phosphatidyl-serine (PS)
externalization, a hallmark of cell death. SKOV-3 cells
were transfected with either negative control (NC),
RGS10 or RGS17 siRNA, and then exposed to vehicle, 1
μM, 10 μM, or 100 μM cisplatin for 48 hours. PS exter-
nalization was assessed using annexin staining and flow
cytometry as described [20]; 20,000 cells were counted
for each data point. We found that cells with reduced
RGS10 or RGS17 expression displayed less cisplatin-
induced cell surface annexin staining (Figure 4). Nota-
bly, both apoptotic and non-apoptotic mechanisms of
cell death may contribute to cisplatin toxicity, and mea-
suring PS externalization at this time point accounts for
cell death by either mechanism. This suggests that low-
ering RGS expression levels blunts the ability of cisplatin
to induce cell death in SKOV-3 ovarian cancer cells. We
also determined the effect of RGS10 knock-down on cell
proliferation by assessing BrdU incorporation (data not
shown). We did not observe a significant effect on the
rates of cell proliferation, suggesting that the observed
effects of RGS knock down on cell number and cell via-
bility reflect a decrease in cell death rather than an
increase in cell proliferation.
MDR-HeyA8 sensitivity to cisplatin cytotoxicity is regulated
by RGS10 expression
To confirm that our observation that direct suppression
of RGS expression by siRNA decreases sensitivity to
chemotherapeutic drug induced cytotoxicity was not
specific to SKOV-3 cells, we also determined the effect
of RGS knock-down on cell viability, cell proliferation,
and cell death in Hey-A8 cells. RGS10 siRNA resulted
in selective loss of RGS 10 transcript (Figure 5A). How-
ever, in our hands RGS17 siRNA resulted in non-selec-
tive knock-down in HeyA8 cells, unlike the selective
effects seen in SKOV-3 cells. Thus, we report here the
effects of only RGS10 siRNA. siRNA transfection
resulted in approximately 80% knock-down of RGS10
transcript MDR-HeyA8 cells and the effects on cell via-
bility and death were strikingly similar to those observed
in SKOV-3 cells. Knock-down of RGS10 transcript
resulted in a small but significant and reproducible
increase in cell viability (Figure 5B). Further, the relative
cell viability in the presence of micromolar doses of cis-
platin (normalized to that seen in the absence of drug)
was significantly higher with RGS10 siRNA knock-down
(Figure 5C). Also similar to results in SKOV-3 cells, we
confirmed that RGS10 knockdown blunts cell death sti-
mulated by cisplatin (Figure 5D), while it has no effect
on cell proliferation, as measured by BrdU incorporation
(data not shown). Thus, RGS10 knock-down has similar
effects in SKOV-3 cells and MDR-HeyA8 cells. Surpris-
ingly, while siRNA transfection resulted in knock-down
of RGS10 transcript in parental HeyA8 cells as well, this
knock-down did not consistently alter cell viability in
the presence of cisplatin (discussed below).
Table 1 Potencies of chemotherapeutics following siRNA treatment in SKOV-3 cells
Scrambled siRNA RGS10 siRNA RGS17 siRNA RGS10 + RGS17 siRNA
Vincristine Potency (nM IC50 +/- SEM) 5. 85 +/- 1.3 12.8 +/- 2.9 58 +/- 8.7 24 +/- 4.8
Docetaxel Potency (nM IC50 +/- SEM) 0.886 +/- 0.432 10.7 +/- 3.7 85 +/- 23 92 +/- 25
Cisplatin Potency (μM IC50 +/- SEM) 10.4 +/- 1.1 23.0 +/- 1.2 27.9 +/- 1.2 57.8 +/- 1.5
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RGS10 and RGS17 suppress AKT activation
Our observation that inhibition of RGS10 and RGS17
expression enhances cell survival in the presence of che-
motherapeutics suggests that endogenous RGS10 and
RGS17 may suppress constitutive survival signals in
ovarian cancer cells. An obvious candidate survival path-
way is the PI3K/AKT pathway, which is activated in
ovarian cancer cells via Gi G-proteins, targets of deacti-
vation by RGS10 and RGS17 [8]. Further, LPA is a
known survival factor for ovarian cancer cells, and it is
constitutively generated and released from ovarian can-
cer cells, resulting in autocrine activation of AKT path-
ways [8,27]. Given that RGS10 and RGS17 selectively
deactivate Gi subunits [23,28], we hypothesized that
RGS10 and RGS17 may inhibit LPA-stimulated AKT
activation. To test this possibility, we serum starved
SKOV-3 cells transfected with control or RGS10 siRNA
to remove serum-bound LPA, and then measured basal
and acute LPA-stimulated AKT phosphorylation. We
did not observe a difference in the ability of LPA to sti-
mulate AKT phosphorylation between cells expressing
endogenous levels of RGS10 and cells with 75-80%
knock-down of RGS10. However, basal AKT phosphory-
lation levels were slightly but consistently and signifi-
cantly higher in cells with reduced RGS expression,
suggesting that endogenous RGS10 expression levels
may function to attenuate AKT-mediated survival sig-
naling (Figure 6A). It is possible that endogenous levels
of RGS proteins are sufficiently high in SKOV-3 cells
that LPA stimulated AKT levels may not be affected
after siRNA knock-down of RGS10, even if RGS10 pro-
teins are capable of negatively regulating LPA stimulated
AKT signaling. To determine if RGS10 and RGS17 are
capable of regulating this effect, we measured LPA-sti-
mulated AKT activation in SKOV-3 cells expressing
basal levels of RGS proteins and cells overexpressing
each isoform. The ability of LPA to stimulate AKT
phosphorylation was markedly blunted in cells overex-
pressing either RGS protein (Figure 6B), suggesting that
RGS10 and RGS17 proteins may deactivate Gi subunits
required for LPA stimulated AKT activation in SKOV-3
cells.
Discussion
Chemoresistance is a significant problem in ovarian can-
cer and prevents a cure until it can be better understood
scientifically and then managed clinically. Refractory
tumors have poorer outcomes and require innovative
strategies to re-sensitize tumors to chemotherapy and/or
require the development of strategic therapeutics that
Figure 4 RGS10 and RGS17 knock-down suppresses cisplatin-
induced cell death. (A) SKOV-3 cells were transiently transfected
with control or RGS-targeted siRNA constructs and treated with
vehicle or 10 μM cisplatin for 48 hours. Cells were then fixed and
stained with annexin V-FITC to quantify externalized phosphatidyl
serine. Cells were analyzed by flow cytometry, and gated to
calculate percentage of cells staining positively for annexin. In each
plot, PI staining intensity is indicated on the y-axis and annexin
staining intensity is indicated on the x-axis. Cells to the bottom and
right of the indicated diagonal line were scored as annexin positive.
(B) The percentage of annexin-positive cells was determined at
each siRNA transfection condition in the presence of increasing
doses of cisplatin. 20,000 cells were analyzed for each data point.
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will bypass chemoresistance. This study introduces
RGS10 and RGS17 as novel mediators of chemoresis-
tance in ovarian cancer cells. After our initial observa-
tions of a correlation between low levels of RGS
transcript expression in acquired chemoresistance, we
established a causative relationship between suppression
of RGS10 and RGS17 and a reduced susceptibility to
chemotherapeutic cytotoxicity. Further, RGS10 and
RGS17 suppress activation of the survival factor AKT.
Based on these data, we propose that suppressed expres-
sion of RGS proteins is part of the molecular mechan-
ism that allows tumorigenic cells to resist
chemotherapy. Our working model of this mechanism
suggests that autocrine or paracrine activation of Gi-
coupled receptors such as LPA receptors activates survi-
val pathways such as those mediated by AKT that
Figure 5 RGS10 alters cytotoxicity of cisplatin in multi-drug resistant HeyA8 cells. (A) RT-PCR indicates selective knock-down of RGS10 48
hours following transfection of MDR-HeyA8 cells with RGS10 siRNA. (B) siRNA mediated knock-down of RGS10 results in increased cell growth as
determined by viability assays. *: p < 0.05 (C) Cisplatin was added at the indicated doses 24 hours after siRNA transfection, and cell viability was
determined 48 hours after drug treatment. Data are shown normalized to cell viability in the absence of drug (100%). Inset: Relative cell viability
of RGS10 siRNA transfected MDR-HeyA8 cells is significantly higher than control transfected cells in the presence of 40 μM cisplatin. **: p < 0.01.
(D) Phosphatidylserine externalization was determined by annexin staining in MDR-HeyA8 cells transfected with control or RGS10 siRNA
following 48 hour incubation with vehicle or 10 μM cisplatin. Annexin staining was determined using flow cytometry as described in Methods.
50,000 cells were analyzed for each data point.
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Figure 6 RGS and RGS17 inhibit AKT activation. (A) SKOV-3 cells transfected with control (NC) or RGS10 (10) siRNA constructs were serum
starved and stimulated with vehicle or LPA at the indicated concentrations for 5 minutes. Control wells were pre-incubated with LY294002, a
PI3K inhibitor, for 1 hour. Cell lysates were analyzed with SDS-PAGE and immunoblotting with anti-phospho AKT antibodies (top) to measure
AKT activation. Phospho-AKT blots were re-probed with GAPDH antibodies as loading controls (bottom). Activation of AKT was quantified by
densitometry of bands and normalized to GAPDH controls. (B) SKOV-3 cells were transfected with either empty vector (V), plasmid encoding HA-
tagged RGS10 (10), or plasmid encoding HA-tagged RGS17 (17). Cells were serum-starved overnight and treated with vehicle or LPA for 5
minutes at 37°C. Control cells were also treated with 10 μM LY294002 (LY) to block activation. Cell lysates were analyzed with SDS-PAGE and
immunoblotting with anti-phospho AKT antibodies (top left) to measure AKT activation, or HA antibodies (top right) to confirm transfection.
Phospho-AKT blots were re-probed with GAPDH antibodies as loading controls (bottom). Activation of AKT was quantified by densitometry of
bands and normalized to GAPDH controls.
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oppose chemotherapy-induced cell death. Thus, we
hypothesize that RGS10 and RGS17 function as tumor
suppressors by blunting endogenous survival pathways.
The level of expression of endogenous RGS proteins cri-
tically determines whether the balance shifts towards
apoptosis or survival (Figure 7).
The current study focuses on the role of RGS10 and
RGS17 in determining chemoresistance in ovarian can-
cer cells. There are over 20 genes encoding mammalian
RGS proteins, and over 30 distinct gene products, ran-
ging from small proteins comprised solely of an RGS
domain which mediates GAP activity, to multi-domain
proteins with multiple targeting and regulatory functions
[29,30]. RGS proteins critically regulate the strength and
duration of G-protein mediated signals by accelerating
the rate by which activated GTP-bound Ga subunits are
deactivated and returned to the inactive GDP-bound
form up to 1000-fold [31]. As a result, RGS proteins are
Figure 7 Model of working hypothesis. We hypothesize that suppression of RGS expression contributes to chemoresistance by indirectly
amplifying autocrine survival signals.
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critical to regulating the kinetics and amplitude of phy-
siological signal transduction cascades. Indeed, profound
physiological effects have been observed in visual and
cardiovascular signaling systems upon loss of RGS
expression [32,33].
RGS10 and RGS17 are among the smallest of the RGS
proteins, lacking well defined functional domains out-
side of the RGS domain. RGS17 is a member of the RZ
(A) subfamily of RGS proteins and preferentially deacti-
vates members of the Gi/o family of G-proteins [28,34].
RGS17 contains a palmitoylation site N-terminal of the
RGS domain, which potentially regulates its subcellular
localization, further impacting G-protein and receptor
selectivity. Clinical expression data available through the
Oncomine database suggests that RGS17 is expressed at
significantly lower levels in ovarian tumors compared to
normal ovary, with expression of RGS17 progressively
decreasing with advancing disease grade [13]. This trend
is consistent with our observation that RGS17 expres-
sion is lost during chemoresistance, although the che-
mosensitivity of the tumors in these datasets was not
reported. Notably, our results are in contrast with a
recent study showing that RGS17, which is overex-
pressed in human lung and prostate cancer [35-37],
induces tumor cell proliferation [38]. In lung cancer
cells, RGS17 proliferative effects are mediated by cAMP
activation of PKA and CREB. We did not observe any
proliferative effects of RGS17 in our system, and it is
unknown if RGS17 can simultaneously activate cAMP/
proliferative pathways and inhibit AKT/survival path-
ways. Further work will determine if this is a cell-type
specific pathway.
RGS10 is a member of the R12 (D) subfamily of RGS
proteins, although RGS10 lacks the multiple regulatory
domains found in other R12 family members. RGS10
has sites for regulatory palmitoylation and phosphoryla-
tion which have been shown to regulate its subcellular
localization. Like RGS17, RGS10 GAP activity is selec-
tive for Gi/o family G-proteins [23]. Changes in RGS10
expression in ovarian cancer have not been reported,
but interestingly it has recently been shown that black
tea polyphenols, which induce apoptosis in human
colon cancer cells, cause acute upregulation of RGS10
expression [39]. Our findings that RGS10 negatively reg-
ulates survival signals suggest that the upregulation of
RGS10 may be linked to polyphenol-induced apoptosis.
While not a major focus of our study, we did observe
consistent down-regulation of RGS2 in chemoresistant
ovarian cancer cells. This is consistent with a report by
Tu and colleagues that RGS2 is down-regulated in
androgen-independent prostate cancer cells, and RGS2
expression suppresses growth in those cells [40].
Our initial findings are based on analysis of previously
reported datasets describing whole-genome expression
changes during acquired chemoresistance in ovarian
cancer [15,16]. In addition to the changes in RGS tran-
scripts, on which we specifically focused, the original
report of transcriptional changes in vincristine-resistant
SKOV-3 cells identified changes in a wide array of genes
associated with chemoresistance. Strikingly, there was
significant overlap between these chemoresistance-
related transcripts and our previously published LPA-
induced transcriptome, transcripts that we identified as
being specifically regulated following LPA treatment in
OVCAR-3 and SKOV-3 cells [15,18]. LPA mediates its
effects by activating a family of GPCRs, which each cou-
ple to heterotrimeric G-proteins and stimulate activation
of the G-protein upon LPA binding to the receptor. It is
the activated G-protein-the target for RGS deactivation
- that mediates the cellular effects of LPA, including
growth, migration, and of particular interest here, survi-
val. Taken together, these observations suggest conver-
gence between transcriptional changes that mediate
chemoresistance and activation of pathways downstream
of LPA.
While there is circumstantial evidence for a role for
LPA survival pathways in the observed link between
RGS proteins and chemoresistance, there are inconsis-
tencies that suggest LPA is at least not the whole story.
For example, we observed that the overexpression of
RGS10 and RGS17 suppressed LPA-stimulated AKT
phosphorylation, while overexpression had inconsistent
effects on cisplatin induced cell death. Conversely,
RGS10 knock-down had significant effects on cell viabi-
lity, but did not significantly affect LPA stimulated AKT
activation. Several potential differences in the experi-
mental conditions could account for this, for example
viability assays to determine cisplatin-induced cellular
toxicity were performed 72 hours following transfection
in the presence of chemotherapeutic drug, while LPA-
stimulated AKT phosphorylation was measured 48
hours after transfection following serum starvation and
acute 5 minute LPA treatment. It is also possible that
the endogenous expression levels of RGS are sufficient
to maximally deactivate G-proteins under basal, auto-
crine LPA stimulating conditions, but following acute
LPA receptor activation, deactivation of G-proteins by
endogenous RGS proteins cannot keep up the with acti-
vation of G-proteins by LPA receptors, making the
effect of exogenous RGS proteins more apparent. How-
ever, other Gi-coupled GPCRs are implicated in ovarian
cancer proliferation and survival signaling, such as
endothelin, chemokine, and prostaglandin receptors
[41-43], suggesting RGS10 and RGS17 may regulate
multiple survival pathways besides LPA.
Similar effects on cell viability and cell death were
seen in SKOV-3 and MDR-HeyA8 cells, which both
show low sensitivity or resistance to certain drugs, but
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the effects were not recapitulated in parental HeyA8
cells. It is possible that additional molecular changes
have occurred in the resistant cells that facilitates survi-
val in the presence of reduced RGS knock-down. It is
also possible that parental HeyA8 cells have sufficiently
high levels of RGS10 expression that knock-down does
not change the rate of G-protein deactivation. In con-
trast, a similar fold knock-down in MDR-HeyA8 cells,
which we shown have several fold lower RGS10 expres-
sion than parental cells, may be sufficient to change the
kinetics of G-protein deactivation. Future research is
required to define the thresholds below which RGS
expression becomes rate limiting and how this survival
mechanism interacts with other survival adaptations
facilitating chemoresistance.
Conclusions
Although medical science is on the verge of developing
novel, selective anti-cancer therapeutics with tumor-spe-
cific targets, “traditional” cytotoxic chemotherapeutic
agents such as platinum compounds and taxanes still
remain a dominant force in the fight against cancer and
are highly effective against specific tumor types. It is cri-
tical to understand the molecular changes that lead to
chemoresistance in order to predict, prevent, and
reverse refractory disease, thereby resurrecting the ther-
apeutic potential of the available arsenal of effective che-
motherapies. Our results establish RGS10 and RGS17 as
novel regulators of cell survival and chemoresistance in
ovarian cancer cells and represents the first link between
any RGS protein and cancer chemoresistance. Our find-
ings are critical to understanding the transitional
changes that tumor cells undergo along the path to che-
moresistance. Establishing this important mechanism
involving RGS10 and RGS17 is the first part of a sys-
tematic evaluation of cellular signaling in ovarian cancer
chemoresistance.
Additional material
Additional file 1: Drug sensitivity of parental HeyA8 cells and multi-
drug resistant (MDR) HeyA8 cells. The viability of each cell line was
determined following 48 hour treatment with various concentrations of
each drug using Cell Titer Blue metabolic viability assays as described.
Additional file 2: Drug sensitivity of SKOV-3 cells. The viability of
SKOV-3 cells was determined following 48 hours treatment with various
concentrations of each drug using Cell Titer Blue metabolic viability
assays as described.
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